News & Events
23 May 2013 EPIC Biotech Conference
22 April 2013 PAGE Meeting 2013
8 April 2013 Physiomics to present new developments of the Virtual Tumour platform and the drugCARD Database at Annual Meeting for American Association for Cancer Research (“AACR”)
25 March 2013 Physiomics launches its cardiac toxicity modelling service
21 March 2013 Workshop Invitation – Half-day workshop on 11th June 2013 at University of Strathclyde (Glasgow)
18 March 2013 Physiomics to offer new Clinical PK/PD service
15 March 2013 Systems Biology Symposium
15 March 2013 1st Coordinating Action Systems Medicine (CASyM) stakeholder conference
Services
Cardiac Toxicity
Physiomics' cardiac toxicity service
Physiomics has developed a new technology for predicting cardiac toxicity that is 50% more accurate than the best current competitor.
Cardiac toxicity is a leading cause of attrition in clinical studies and post-marketing withdrawal- All candidate drugs must be screened for activity against the hERG potassium channel (FDA requirement)
- Optimal design of future studies
- Physiomics' technology takes into account activity against hERG and two additional ion channels (hNav1.5 and hCav1.2) to deliver 50% greater predictivity than the best model currently available
Clinical PK/PD
Physiomics' clinical PK/PD service
We can offer Model Based Drug Development (MBDD) services which include:
- Population PKPD analysis of clinical data – select the right dose and regimen to maximise efficacy and minimise safety concerns
- Back-translational analysis – place emerging early clinical data within the context of the pre-clinical data package
- Optimal design of future studies – minimise no. of measurements to maximise information
- Preparation for due diligence – merge pre-clinical and clinical data to provide a holistic view of the compound
Virtual Tumour Platform
Physiomics' Virtual Tumour platform predicts optimal drug dosing, scheduling and combinations.
Physiomics helps pharmaceutical and biotechnology companies to determine optimal doses, schedules and combinations for their pre-clinical oncology candidates.
Virtual Tumour provides the following key benefits:
- Improve success rates for oncology candidates entering clinical studies, by increasing efficacy
- Reduce the time taken to do proof-of-principle
studies - Reduce the cost of xenograft study programmes
(fewer experiments needed) - Provide regulatory agencies with a rationale for the design of a clinical study programme
